David Holland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Holland has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Dragana Drinkovic
LabPlus, Auckland Healthcare, Auckland, New Zealand
2 shared publicationsSally Roberts
Microbiology Laboratory, Auckland, New Zealand
2 shared publicationsSusan Taylor
Microbiology Laboratory, Middlemore Hospital, Auckland, New Zealand
2 shared publicationsAlison Wesley
Starship Children's Hospital, Auckland, New Zealand
1 shared publication- Arlo Upton
Labtests, Auckland, New Zealand
1 shared publication Bart J. Currie
Menzies School of Health Research and Northern Territory Clinical School, Darwin, Australia
1 shared publication
Latest Publications
- Open Access
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , e138-e140
Cystic Fibrosis andBurkholderia pseudomalleiInfection: An Emerging Problem?
We recently managed 4 patients with cystic fibrosis who had acquired Burkholderia pseudomallei infection after exposure in a region of endemicity. Person-to-person transmission between 2 siblings may have occurred; otherwise, the evidence suggests that cystic fibrosis may increase the likelihood of infection with this organism, and patients should be warned of this possibility and cautioned to avoid high-risk activities.
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , e138-e140
Open AccessCystic Fibrosis andBurkholderia pseudomalleiInfection: An Emerging Problem?
We recently managed 4 patients with cystic fibrosis who had acquired Burkholderia pseudomallei infection after exposure in a region of endemicity. Person-to-person transmission between 2 siblings may have occurred; otherwise, the evidence suggests that cystic fibrosis may increase the likelihood of infection with this organism, and patients should be warned of this possibility and cautioned to avoid high-risk activities.
- Open Access
- 1 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (11) , 1434-1440
CorynebacteriumSpecies Isolated from Patients with Mastitis
Corynebacteria were isolated from breast tissue, pus, or deep wound swabs of 24 women; the most common species isolated was the newly described Coryn
- 1 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (11) , 1434-1440
Open AccessCorynebacteriumSpecies Isolated from Patients with Mastitis
Corynebacteria were isolated from breast tissue, pus, or deep wound swabs of 24 women; the most common species isolated was the newly described Coryn
- 23 August 2002
- Vol. 115 (1160) , U145
Vancomycin-resistant enterococcal colonisation of hospitalised patients in Auckland.
To assess the prevalence of vancomycin-resistant enterococcal colonisation of hospitalised patients in five selected Auckland hospitals. Faeces specimens submitted to the Microbiology Laboratories at Auckland and Middlemore Hospitals for Clostridium difficile toxin assay were screened for the presence of vancomycin-resistant enterococci (VRE). VRE were cultured from two of 686 patients, giving a colonisation rate of 0.3% in those patients who had a faeces sample submitted for C. difficile toxin assay (95% CI 0 to 0.7%). Both isolates were Enterococcus faecalis; susceptible to ampicillin, resistant to vancomycin and of the vanA genotype. This is the first screening study in New Zealand that has identified patients with VRE colonisation. While VRE are still rarely isolated in this country, rates of colonisation and infection may be increasing. Hospitals need to be aware of the likely emergence of VRE and be prepared to implement strategies to limit their spread.
- 23 August 2002
- Vol. 115 (1160) , U145
Vancomycin-resistant enterococcal colonisation of hospitalised patients in Auckland.
To assess the prevalence of vancomycin-resistant enterococcal colonisation of hospitalised patients in five selected Auckland hospitals. Faeces specimens submitted to the Microbiology Laboratories at Auckland and Middlemore Hospitals for Clostridium difficile toxin assay were screened for the presence of vancomycin-resistant enterococci (VRE). VRE were cultured from two of 686 patients, giving a colonisation rate of 0.3% in those patients who had a faeces sample submitted for C. difficile toxin assay (95% CI 0 to 0.7%). Both isolates were Enterococcus faecalis; susceptible to ampicillin, resistant to vancomycin and of the vanA genotype. This is the first screening study in New Zealand that has identified patients with VRE colonisation. While VRE are still rarely isolated in this country, rates of colonisation and infection may be increasing. Hospitals need to be aware of the likely emergence of VRE and be prepared to implement strategies to limit their spread.
- Open Access
- 1 August 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 48 (2) , 315-316
Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance
Correspondence ment with clindamycin, again with the development of clindamycin resistance. 5 Just how often and how quickly resistant mutants develop in vivo where host, bacterial and antimicrobial factors interact is unknown. The conclusion is that this event certainly occurs and the accumulating clinical evidence indicates that it is not rare. We will now be very cautious about using clindamycin in patients with major infections due to S. aureus expressing ICR, especially where treatment is likely to be prolonged or infection difficult to eradicate.
- 1 August 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 48 (2) , 315-316
Open AccessClindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance
Correspondence ment with clindamycin, again with the development of clindamycin resistance. 5 Just how often and how quickly resistant mutants develop in vivo where host, bacterial and antimicrobial factors interact is unknown. The conclusion is that this event certainly occurs and the accumulating clinical evidence indicates that it is not rare. We will now be very cautious about using clindamycin in patients with major infections due to S. aureus expressing ICR, especially where treatment is likely to be prolonged or infection difficult to eradicate.